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Abstract
 
T cell receptor (TCR)-interacting molecule (TRIM) is a recently identified transmembrane
adaptor protein, which is exclusively expressed in T cells. Here we demonstrate that in mature
 
T cells, TRIM preferentially interacts with the TCR via the TCR
 
-
 
 
 
 chains and to a lesser ex-
tent via the CD3-
 
 
 
/
 
 
 
 heterodimer. Transient or stable overexpression of TRIM in Jurkat T
cells results in enhancement of TCR expression on the cell surface and elevated induction of
 
Ca
 
2
 
 
 
 mobilization after T cell activation. TRIM-mediated upregulation of TCR expression re-
sults from inhibition of spontaneous TCR internalization and stabilization of TCR complexes
on the cell surface. Collectively, our data identify TRIM as a novel integral component of the
TCR complex and suggest that one function of TRIM might be to modulate the strength of
signals transduced through the TCR through regulation of TCR expression on the cell surface.
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Introduction
 
Hematopoietic antigen receptors such as the TCR, the B
cell receptor, or Fc receptors are generally composed of at
least two different subunits, one representing the ligand
binding site, the other being responsible for signal trans-
duction after receptor engagement. The molecular struc-
ture of these two subunits reflects their different tasks for
eliciting cellular responses. Thus, the ligand binding site
normally comprises a long extracellular domain (serving as
recognition element), an 
 
 
 
-helical transmembrane domain
that carries at least one charged amino acid, and a very
short cytoplasmic segment devoid of any signaling motifs.
In contrast, the signal-transducing component is composed
of a very short extracellular domain (lacking an external
ligand), a transmembrane domain that also contains a
charged amino acid (to allow stable interaction with the
ligand binding subunit), and a comparably long cytoplasmic
tail carrying particular amino acid motifs, which are neces-
sary for signal transduction. These tyrosine-based signaling
motifs have been termed immunoreceptor tyrosine-based
activation motifs (ITAMs) and comprise the sequence
YxxL(x)
 
7–8
 
YxxL (x 
 
 
 
 nonconserved amino acid). After
binding of an external ligand (e.g., antigen), ITAMs be-
come phosphorylated by protein tyrosine kinases of the src
family such as Lck, Fyn, and Lyn, and this initial phos-
phorylation event then allows propagation of the signal
from the cell surface into the cytoplasmic compartment (1).
In the case of the TCR, the ligand binding site is con-
structed from the polymorphic 
 
 
 
- and 
 
 
 
 chains, which
form a disulfide-linked heterodimer that interacts with
peptide/MHC complexes presented on the surface of anti-
gen presenting cells (2–4). Signal transduction after binding
of antigen/MHC to the TCR is then mediated via the
 
TCR-associated components of the CD3 complex (CD3 
 
 
 
,
-
 
 
 
, and -
 
 
 
) and the 
 
 
 
 chains (5–9). However, besides serv-
ing as signal transducing elements for the TCR, expression
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of the CD3 molecules and 
 
 
 
 chains is required for proper
assembly of the TCR complex and its transportation to and
expression on the cell surface. Loss of each of the individual
members of the CD3 complex or the 
 
 
 
 chains results in the
synthesis of unstable TCRs which cannot be transported to
the cell surface and become either degraded in lysosomes
(in the case of hexameric 
 
      
 
-TCRs lacking 
 
 
 
) or in
the endoplasmic reticulum (in the case of TCRs lacking
any component of the TCR/CD3 complex besides 
 
 
 
; ref-
erences 10–14).
Although it now seems clear that all components neces-
sary for efficient assembly, transportation, and cell surface
expression of the TCR have been identified (15), it is not
yet fully understood how the expression levels of the TCR
on the cell surface are regulated. Based on analysis of 
 
 
 
-defi-
cient murine T cell hybridomas, it was proposed that the
availability of 
 
 
 
 might be the limiting factor that determines
how many TCRs are expressed on the cell surface (11).
Thus, although all components of the TCR are synthesized
in large amounts, relatively few 
 
 
 
 molecules are synthesized
by T cells (
 
 
 
10% compared with other TCR/CD3
chains). As only TCR/CD3 complexes that are associated
with 
 
 
 
 can be transported to the plasma membrane whereas
those devoid of 
 
 
 
 are degraded in lysosomes, the amount of
available 
 
 
 
 regulates cell surface expression of the TCR.
However, the 
 
 
 
 chain only loosely associates with the
TCR. Indeed, a recent report demonstrated that in Jurkat
T cells, 
 
 
 
 is transported to the Golgi apparatus indepen-
dently from other TCR chains (16). Moreover, it had been
suggested that in human peripheral blood T cells and in the
Jurkat T cell line, 
 
 
 
 chains cycle independently from the
other components of the TCR (17). Thus, the majority of
the 
 
 
 
 chains that are expressed on the cell surface are rap-
idly internalized, degraded in lysosomes, and replaced by
newly synthesized 
 
 
 
, whereas the turnover of the remaining
TCR/CD3 complex seems to be much slower. The signif-
icance of the rapid turnover of TCR-
 
 
 
 and its partial inde-
pendence from the other components of the TCR is un-
clear at present. Neither is it understood to what extent the
turnover of 
 
 
 
 can influence the expression or function of
the TCR/CD3 complex (for a review about the fate of the
TCR, see reference 18)
Recently we reported the identification and molecular
cloning of a novel transmembrane adaptor protein termed
TCR-interacting molecule (TRIM)
 
1
 
 (reference 19). Based
on the findings that TRIM coprecipitates with the TCR in
resting T lymphocytes and various T cell lines as well as our
observation that TRIM expression is strongly downregu-
lated after modulation of the TCR from the cell surface, we
had proposed that TRIM represents a so far uncharacterized
integral component of the TCR/CD3/
 
 
 
 complex. How-
ever, the function of TRIM is not yet clear. In addition, it
is not known how the interaction between TRIM and the
 
TCR is mediated and whether TRIM plays a role in the as-
sembly and/or the cell surface expression of the TCR/
CD3/
 
 
 
 complex. Here we have addressed these questions
by studying the association between TRIM and the TCR
in peripheral blood T lymphocytes and in Jurkat T cells.
 
Materials and Methods
 
Cells.
 
Jurkat T cells and COS cells were maintained in
RPMI 1640 (GIBCO BRL) supplemented with 10% FCS
(GIBCO BRL), 1% penicillin-streptomycin (GIBCO BRL), and
2% glutamine (GIBCO BRL) at 37
 
 
 
C and 100% humidity. The
Jurkat variants 18B3 (lacking TCR-
 
 
 
), JBN (lacking TCR-
 
 
 
),
and JGN (lacking CD3
 
 
 
; provided by Dr. C. Geisler, Institute of
Medical Microbiology and Immunology, University of Copen-
hagen, Copenhagen, Denmark) have been described previously
(16). Peripheral blood T lymphocytes were prepared by E-roset-
ting from freshly drawn venous blood of healthy donors as de-
scribed elsewhere (20).
 
cDNA Constructs and Molecular Cloning of the Mouse TRIM
cDNA.
 
The cDNA constructs encoding wild-type TRIM,
TRIM/linker for activation of T cells (LAT) chimeras, and
TRIM mutants that were used in this study are all based on
the TRIM cDNA constructs that we have described previously
(19). They were generated by in vitro mutagenesis using the
QuickChange™ site directed mutagenesis kit (Stratagene) ac-
cording to the manufacturer’s instructions. All constructs were
verified by DNA sequencing. A mouse TRIM cDNA clone (se-
quence data are available from GenBank/EMBL/DDBJ under
accession no. AJ29769) was isolated by screening a mouse spleen
cDNA library at low stringency with a human TRIM probe ac-
cording to standard procedures.
 
Transfection Experiments.
 
Jurkat cells were transfected by elec-
troporation and stable clones selected in hygromycin-containing
medium as described previously (21). For transfection of COS
cells, 2 
 
 
 
 10
 
5
 
 exponentially growing cells were incubated over-
night in a six-well plate (Nunc). Adherent cells were washed
twice with 2 ml of PBS and incubated for 4 h in 1 ml of transfec-
tion solution (2 
 
 
 
g DNA, 10 mg/ml DEAE-dextran, 5.6 mg/ml
chloroquine in RPMI 1640 supplemented with 2% FCS). Subse-
quently, the solution was removed and 1 ml of a 10% DMSO
(Merck) in RPMI was added and allowed to incubate for 2 min.
Then cells were washed once with PBS and incubated for 36 h in
2–3 ml of culture medium. Transfected cells were washed in PBS
and further processed for immunoprecipitation or confocal laser-
scan microscopy.
 
Abs.
 
The following monoclonal and polyclonal Abs were
used for immunoprecipitation, confocal laser scan microscopy,
Western blotting, and indirect immunofluorescence: HLA-I
(W6/32, for FACS
 
®
 
 analysis and cap formation), anti-
 
 
 
 mAb,
clone 6B10.2 (Santa Cruz Biotechnology, Inc.; confocal laser
scan analysis and immunoprecipitation), anti-
 
 
 
 (H146 from ham-
ster; a gift of Dr. K. Campell, Fox Chase Cancer Center, Phila-
delphia, PA; for immunoprecipitation), anti-
 
 
 
 clone 1C10 (West-
ern blotting; donated by Dr. M. Peter, University of Chicago,
Chicago, IL), CD3
 
 
 
 mAb OKT3 (for cocapping and FACS
 
®
 
analysis), CD3
 
 
 
 
 
clone SP34 (from M. Peter), CD3
 
 
 
 
 
clone
2Ad2a2 (IgM; donated by Dr. E. Reinherz, Dana Farber Cancer
Center, Boston, MA; for modulation experiments), PE-labeled
CD3
 
 
 
 clone UCHT-1 (BD PharMingen), and anti-TCR mAb
BMA-031 (a gift from Dr. Kurrle, Hoechst AG, Frankfurt, Ger-
many; for FACS
 
®
 
 analysis). To raise mouse mAbs to the intracel-
 
1
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 BFA, brefeldin A; LAT, linker for activa-
tion of T cells; SIT, SHP2-interacting transmembrane adaptor protein;
SKAP-HOM, Src kinase–associated phosphoprotein homologue; TRIM,
TCR-interacting molecule. 
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lular domain of TRIM, F
 
1
 
(BALB/c 
 
 
 
 B10.A) hybrid mice were
immunized with a TRIM cytoplasmic fragment corresponding to
amino acid residues 29–186 of human TRIM. For bacterial ex-
pression, a cDNA fragment encoding this intracellular part of
TRIM was cloned into the BamHI site of the pET-15b expres-
sion vector (Novagen), generating a construct with NH
 
2
 
-terminal
His tag. The protein was isolated from bacterial lysates by affinity
chromatography and used for intrasplenic immunization followed
by standard procedures to produce Ab-secreting hybridomas.
Two anti-TRIM mAbs were used in this study, namely TRIM-4
and TRIM-7. The protein A–purified Abs were covalently linked
to CNBr-activated sepharose beads at a concentration of 6 mg/
ml. Polyclonal antisera directed at mouse CD3
 
 
 
, -
 
 
 
, and -
 
 
 
 used
for Western blotting have been described previously (22) and
were donated by Dr. E. Palmer (Basel Institute for Immunology,
Basel, Switzerland). Affinity-purified polyclonal anti-TRIM, anti-
Src kinase–associated phosphoprotein homologue (SKAP-HOM),
and anti-lymphocyte phosphatase-associated protein (LPAP) anti-
sera were prepared as described elsewhere (19, 23, 24) and used at
5–10 
 
 
 
g/ml for confocal laser scan analysis. Anti-TCR mAb
C305 (IgM) was a gift of Dr. A. Weiss (University of California at
San Francisco, San Francisco, CA) and used as culture superna-
tant. For the capping experiment shown in Fig. 1 B, the follow-
ing Abs (all IgM) were used: CD4 (MEM-16), CD5 (MEM-128),
and CD28 (248.23.2; reference 25).
 
Cocapping Experiments.
 
Resting peripheral blood T cells were
washed twice with RPMI (without FCS) and adjusted to 7 
 
 
 
10
 
6
 
/ml in RPMI 1640. 10 
 
 
 
l of this suspension was pipetted onto
each reaction field of an adhesion slide (Bio-Rad Laboratories) and
allowed to adhere for 10 min at room temperature. Adherent cells
were washed twice with RPMI and the slide was blocked for 15
min with complete culture medium. Cap formation was subse-
quently induced by incubating the cells for 15 min with 15 
 
 
 
l
mAb solution (concentration 10 
 
 
 
g/ml
 
 
 
in complete culture me-
dium), followed by two washes with RPMI 1640 (50 
 
 
 
l per field)
and cross-linking of the primary Abs with 15 
 
 
 
l of Texas red–
labeled donkey anti–mouse antiserum (Dianova; diluted 1:50 vol/
vol in culture medium) for 35 min at room temperature in the
dark. Capped cells were washed twice with 50 
 
 
 
l PBS supple-
mented with 0.2% NaN
 
3
 
 and then fixed for 3 min with methanol
(stored at 
 
 
 
20
 
 
 
C). The methanol was removed and the cells were
fixed for an additional 5 s with ice-cold acetone. Fixed cells were
washed twice with PBS and blocked again for 10 min with PBS/
1% BSA at room temperature. Subsequently, affinity-purified
polyclonal Abs directed at TRIM, SKAP-HOM, and LPAP were
added (15 
 
 
 
l per field, concentration 10 
 
 
 
g/ml) and incubated for
30 min at room temperature in the dark. The Ab-labeled cells
were then washed once with PBS/BSA (40 
 
 
 
l per field) and three
times with PBS. Then, 15 
 
 
 
l of the secondary Cy2-labeled don-
key anti–rabbit Ab (Dianova) was added (concentration 1:125 vol/
vol in PBS/1% BSA) and incubated for 30 min s at room temper-
ature in the dark. Cells were washed once with PBS/BSA, three
times with PBS, and finally for at least 5 min with distilled water.
The slides were then covered with a cover slip, which was fixed
with Elvanol (Calbiochem) for at least 16 h.
For colocalization studies in transfected Jurkat T cells or COS
cells, cells were subjected to adhesion slides and fixed with meth-
anol and acetone as described above. Fixed cells were then incu-
bated with 10 
 
 
 
l CD3
 
 
 
 mAb 6B10.2 (10 
 
 
 
g/ml in PBS/1%
BSA) and incubated for 30 min at room temperature. The stained
cells were then washed with PBS/1% BSA for 3 min and three
more times with plain PBS. Then, 10 
 
 
 
l of Cy2-labeled donkey
anti–mouse antiserum were added (Dianova; diluted 1:150 vol/
 
vol in PBS/1% BSA) and incubated for 30 min at room tempera-
ture. For detection of FLAG-tagged molecules, cells were incu-
bated with 10 
 
 
 
l of biotinylated anti-FLAG Ab (M2; 10 
 
 g/ml
in PBS/BSA; Sigma-Aldrich) for 30 min at room temperature,
washed as above, and incubated again for 30 min at room tem-
perature with 10  l of streptavidin–Texas red solution (1:100
vol/vol in PBS/1% BSA). Cells were then washed again and the
slide preparation finished as described above. For detection of
TRIM, essentially the same steps were conducted with the ex-
ception that Texas red–labeled donkey anti–rabbit Ab (Dianova;
diluted 1:125 vol/vol in PBS/1% BSA) was used as second step
reagent. Slides were viewed on a Laserscan microscope (Ernst Leitz
GmbH) using 570 nm (red emission) and 508 nm (green emis-
sion) filters, respectively. In general, the magnification was  40.
Analysis of Spontaneous TCR Internalization. Jurkat T cells
were either transfected with empty vector or with a cDNA con-
struct encoding wild-type TRIM. 40 h later, 107 cells were incu-
bated on ice with PE-labeled mAb UCHT-1 for 30 min in pre-
cooled HBSS (GIBCO BRL) supplemented with 2% FCS.
Unbound Abs were removed by washing and the externally la-
beled cells were then resuspended in 4 ml prewarmed medium
(37 C) for the indicated periods of time. The reaction was termi-
nated by adding 4 ml of ice-cold HBSS/2% FCS/0.1% NaN3 and
the cells were pelleted by centrifugation. After removing the su-
pernatant, cells were resuspended in 100  l of ice-cold C305
(anti-TCR, IgM) hybridoma culture supernatant and incubated
on ice for 30 min. After washing, cells were incubated on ice
with a 1:40 vol/vol (in HBSS/2% FCS/0.1% NaN3) dilution of a
FITC-labeled polyclonal goat anti–mouse IgM serum for 20 min,
washed, and further analyzed by flow cytometry and confocal la-
ser scanning microscopy.
Intracellular Ca2  Mobilization. Ca2  flux in response to TCR
ligation was investigated using variable wavelength Ca2  indica-
tors according to standard protocols. Jurkat T cell clones were
loaded with 4  M fura-2 AM (Molecular Probes Inc.) for 30 min
at 37 C. Dye-loaded cells were washed and incubated on ice
with C305 anti-TCR IgM mAb for 30 min before centrifugation
and resuspending in warm serum-free medium. Fluorescence in-
tensity was measured on a PerkinElmer luminescence spectrome-
ter LS50 with excitation at 340 and 380 nm and emission fixed at
510 nm. Cells were maintained at 37 C with continuous gentle
stirring throughout the analysis. Maximum fluorescence (Fmax)
was determined by lysing the cells with 0.1% Triton X-100 and
minimum fluorescence (Fmin) by the addition of 40 mM Tris, 4
mM EGTA. [Ca2 ]i was calculated using FL WinLab software
according to the Grynkiewitz equation: 
where Kd   135 nM for fura-2 AM and Ca2  and where R is F
at 340 nm/F at 380 nm, and Sf (or Sb) is Fmin (or Fmax) at 380 nm.
Cell Surface Biotinylation and Other Experimental Procedures.
For biotinylation of cell surface molecules, Jurkat T cells were
washed twice with ice cold PBS, adjusted to 10   106 cells/ml,
and labeled with 100  l biotin (10 mg/ml in PBS; Pierce Chem-
ical Co.) for 20 min at 4 C. The reaction was stopped by adding
an equal volume of ice cold PBS supplemented with 10 mM gly-
cine for 5 min, and the externally labeled cells were then washed
twice with PBS to remove unbound biotin. 35   106 cells were
then lysed in 2 ml of lysis buffer supplemented with 1% digitonin
and postnuclear supernatants were subjected to immunoprecipita-
tion using 75  l of packed CNBr-activated Sepharose beads cou-
pled with protein A–purified CD3  mAb OKT-3 (6 mg mAb/ml
Ca
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of packed beads). After washing, the beads pellet was resuspended
in 75  l of lysis buffer supplemented with 1% Triton X-100 and
0.5% SDS and incubated for 5 min at 95 C. The SDS was
quenched by adding 1.25 ml of lysis buffer, the beads were spun
down, and the supernatant carefully removed and subjected to re-
precipitation using either polyclonal rabbit antisera directed at
CD3 , - , and -  or a mAb directed at   (H146). After 14%
SDS-PAGE, samples were blotted onto nitrocellulose which was
then revealed by peroxidase-labeled streptavidin followed by en-
hanced chemoluminescence (ECL) detection.
Immunoprecipitation, Western blotting, and FACS® analysis
were essentially performed as described elsewhere (19, 20, 26).
Results
TRIM Is a Novel Integral Component of the TCR/CD3/ 
Complex. Recently, we reported the molecular cloning of
a novel 29/30-kD disulfide-linked transmembrane adaptor
protein called TRIM (19). We had chosen the name TRIM
because several lines of evidence had suggested that this
novel polypeptide preferentially interacts with the TCR/
CD3/  complex. For example, in transformed human T
cell lines such as HPB-ALL, TRIM coprecipitates with
CD3  but not with CD4, CD8, CD28, or CD45 when us-
ing the detergent digitonin. In addition, in nontransformed
peripheral blood T lymphocytes and the cutaneous T cell
lymphoma PBLCPCS, the expression levels of TRIM in
total cellular lysates are strongly downregulated after ligand-
induced modulation of the TCR, whereas the expression
levels of, e.g., CD8 and HLA class I remain unchanged (19).
To provide additional evidence for an association between
TRIM and the TCR in vivo in intact and nontransformed
cells, human peripheral blood T lymphocytes were incubated
with mAbs directed at the extracellular domains of CD3 , or
as a control HLA class I followed by induction of cap forma-
tion using goat anti–mouse polyclonal antiserum. Subse-
quently, the subcellular localization of TRIM was deter-
mined by confocal laser scan microscopy. The top left panel
of Fig. 1 A indicates that under these experimental condi-
tions, TRIM cocaps with the TCR. In contrast, under the
same experimental conditions, TRIM does not cocap with
HLA class I molecules (top right panel of Fig. 1 A). Similarly,
TRIM does not cocap with the CD4, CD5, and CD28
coreceptors (Fig. 1 B). Finally, as shown in the bottom panels
of Fig. 1 A, cocapping with the TCR is a particular property
of TRIM, as other cytoplasmic and/or transmembrane adap-
tor proteins such as SKAP-HOM or LPAP do not colocalize
with capped CD3  under the same experimental conditions.
Thus, these data further confirm that TRIM represents a
novel component of the TCR/CD3/  complex.
Regulation of TCR Expression by TRIM. We next as-
sessed whether the association between TRIM and the
TCR might be of functional relevance. To this end we tran-
siently overexpressed F-TRIM in Jurkat cells and analyzed
the expression levels of the TCR- /  heterodimer and of
CD3  by indirect immunofluorescence using the mAbs
BMA031 (TCR- / ) and OKT-3 (detecting CD3 /  and
CD3  /  heterodimers), respectively. As demonstrated in
Fig. 2 A, overexpression of TRIM resulted in a considerable
Figure 1. Interaction between TRIM and the TCR in peripheral blood T cells. (A) Top: T cells were incubated with CD3  (OKT3) or anti-HLA I
(W6/32) mAbs followed by induction of cap formation using Texas red–labeled donkey anti–mouse Ab. Cells were fixed and the subcellular localization
of TRIM determined using polyclonal TRIM Ab and Cy2-labeled donkey anti–rabbit antiserum. Bottom: subcellular localization of SKAP-HOM (left)
and LPAP (right) in TCR-capped peripheral blood T cells. (B) T cells were incubated with mAbs directed at CD3, CD4, CD5, and CD28 (all of the IgM
isotype) to induce cap formation. Cells were fixed and the distribution of TRIM determined using biotinylated TRIM mAb (TRIM-4) followed by
streptavidin Texas red. In parallel, cap formation was monitored by incubating the IgM-treated cells with a FITC-labeled goat anti–mouse IgM antiserum.1273 Kirchgessner et al.
increase in TCR- /  and CD3  expression on the cell sur-
face, whereas the expression levels of CD28 and HLA class I
remained unchanged. Analysis of the mean channels of fluo-
rescence of TCR expression indicated that TRIM transfec-
tants expressed approximately twice as many TCRs on the
cell surface as vector transfectants. In contrast, overexpres-
sion of the transmembrane adaptor proteins LAT or SHP2-
interacting transmembrane adaptor protein (SIT) did not
influence the expression levels of the TCR under the same
experimental conditions (not shown here but see Figs. 3 C
and 6 C). This suggests that upregulation of TCR expres-
sion is a particular property of TRIM and that it is not sim-
ply induced by transfecting the cells. The data depicted in
Fig. 2 B further indicate that overexpression of TRIM does
not substantially alter the subunit composition of the TCR/
CD3/  complexes that are expressed on the cell surface.
TRIM Inhibits Spontaneous Internalization of TCR/CD3/ 
Complexes. Despite the fact that overexpression of TRIM
leads to enhanced expression of all TCR subunits on the
cell surface, the overall amounts of CD3  and TCR-  in
total lysates remain rather unchanged (Fig. 3 A). This sug-
gests that the functional effect of TRIM cannot be simply
explained by an increase in protein synthesis of particular
TCR components. Therefore, we argued that TRIM
might enhance TCR expression on the cell surface by ei-
ther facilitating transportation of preassembled TCR com-
plexes to the cell surface or by preventing spontaneous
TCR internalization. To obtain first insights on whether
one of these mechanisms could play a role in TRIM-medi-
ated upregulation of TCR expression, we compared the
subcellular localization of   in Jurkat T cells transfected
with either empty vector or with a cDNA encoding F-TRIM
using confocal laser scan microscopy.
The left panel of Fig. 3 B depicts that in vector-trans-
fected cells, similar fractions of endogenous   localize at
the plasma membrane and in an intracellular compartment.
This pattern of  -distribution within the cell seems to be
typical for Jurkat T cells and resting peripheral blood T
cells (16). In marked contrast, in Jurkat cells transfected
with the plasmid encoding F-TRIM, most   molecules lo-
calize at the plasma membrane (Fig. 3 B, right panel) and
only some cells show the typical intracellular localization
of    that is visible in vector transfectants. To analyze
whether the latter cells are those which had not been
transfected, we performed double immunofluorescence
using anti-  (green fluorescence, Cy2) and anti-FLAG (red
fluorescence, Texas red) mAbs, respectively. The top and
middle panels of Fig. 3 C show that endogenous   is tar-
geted to the cell membrane only in cells expressing
F-TRIM, whereas in cells which do not express F-TRIM
or which express only very low amounts of the molecule,
a fraction of   is still present in the cytoplasmic compart-
ment. Thus, overexpression of TRIM in Jurkat T cells in-
creases the amounts of   at the plasma membrane and con-
comitantly decreases its intracellular pool. This is a specific
property of TRIM, as overexpression of the transmem-
brane adaptor protein SIT does not alter the subcellular lo-
calization of   (Fig. 3 C, bottom panel). Collectively, these
data indicate that one of the above discussed mechanisms
likely is responsible for TRIM-mediated upregulation of
TCR expression.
To distinguish between the two possibilities, we next in-
cubated vector transfectants and TRIM transfectants with
brefeldin A (BFA) and monitored BFA-mediated downreg-
ulation of TCR expression by flow cytometry. BFA inhibits
exocytosis of proteins while leaving endocytic processes
largely unaffected (27). Thus, we argued, that if TRIM up-
regulates transportation of preassembled TCR complexes to
the cell surface, BFA treatment should lead to an accelerated
loss of cell surface–expressed TCR complexes in TRIM
transfectants compared with vector transfectants. In contrast,
if TRIM would inhibit spontaneous endocytosis of TCR
complexes, one would expect that TRIM transfectants are
less sensitive to BFA treatment than vector transfectants.
As reported previously (28), BFA treatment of vector-
transfected Jurkat T cells induced only an  20% downreg-
ulation of TCR expression (Fig. 4 A). This contrasts the
Figure 2. Overexpression of TRIM in
Jurkat cells results in upregulation of TCR
expression. (A) Jurkat T cells were tran-
siently transfected with empty vector or
with a cDNA construct encoding FLAG-
tagged wild-type TRIM. 16 h later, expres-
sion of the TCR- / , CD3 , CD28, or
HLA class I on the cell surface was deter-
mined by flow cytometry. (B) Jurkat T cells
were transfected with empty vector or with
a cDNA coding for F-TRIM. After 40 h,
cell surface molecules expressed by vector
transfectants and TRIM transfectants were
biotinylated. Cells were then lysed in digi-
tonin-containing buffer and subjected to
CD3  immunoprecipitation. After washing, the precipitated molecules
immunoprecipitates were boiled in SDS-containing buffer and the re-
leased material subjected to reprecipitation using either polyclonal Abs di-
rected at CD3 , CD3 , or CD3 , or a mAb directed at  . The secondary
immunoprecipitates were separated on 14% reducing SDS-PAGE, blotted
onto nitrocellulose, which was then probed with peroxidase-labeled
streptavidin followed by ECL detection.1274 Regulation of TCR Expression by TRIM
situation in T cell hybridomas in which BFA treatment has
been reported most recently to induce a much stronger
downregulation of TCR expression (29). Nevertheless, in
Jurkat T cells overexpressing TRIM, BFA had almost com-
pletely lost its capability to induce downregulation of TCR
expression. This suggests that the higher levels of TCR ex-
pression in Jurkat T cells overexpressing TRIM likely result
from TRIM-mediated inhibition of spontaneous TCR in-
ternalization rather than from facilitating transport of newly
synthesized receptors to the cell surface.
To substantiate this assumption we transfected Jurkat T
cells with empty vector or with a cDNA encoding TRIM.
40 h later, cells were externally labeled with a PE-labeled
CD3  mAb (UCHT1) on ice. After washing, cells where
shifted to 37 C for increasing periods of time and then ex-
ternally labeled with an IgM Ab directed at the anti–TCR-
 /  heterodimer (C305). These cells were then subjected
to FACS® analysis as well as analysis by confocal laserscan-
ning microscopy.
As shown in Fig. 4 B, in both vector and TRIM trans-
fectants the PE signal does not substantially decline even af-
ter a 90-min incubation at 37 C. An extended kinetics
even revealed that the PE signal remains stable for up to 18 h
(not shown). These findings rule out the possibility that the
Figure 3. Overexpression of TRIM in
Jurkat T cells alters the subcellular localiza-
tion of  . (A) Lysates of Jurkat T cells trans-
fected with empty vector or a cDNA cod-
ing for F-TRIM were analyzed for the
expression of CD3  (using mouse mAb
SP34), TCR-  (using mouse mAb 1C10),
and F-TRIM (anti-FLAG) by Western
blotting. (B) Jurkat T cells were transfected
with empty vector alone (left) or with a
cDNA construct encoding F-TRIM (right).
40 h later, the subcellular localization of  
(using mAb 6B10.2) was determined by
confocal laser scan microscopy. Nuclei were
stained with propidium iodine. (C) Cells
were transfected as in B and the subcellular
localization of   (mAb 6B10.2, green fluor-
escence, Cy2) or F-TRIM determined by
confocal laserscan analysis. F-TRIM was
detected using a biotinylated anti-FLAG
Ab. Bottom: specificity control showing
that overexpression of the transmembrane
adapter protein SIT does not alter the sub-
cellular localization of  . Note that addi-
tional data indicating that overexpression of
SIT also does not influence the expression
levels of the TCR on the cell surface are
shown in Fig. 6.1275 Kirchgessner et al.
CD3  molecules become degraded intracellularly (e.g.,
in lysosomes) after shifting the temperature to 37 C and
thus confirm previous data showing that the TCR/CD3
complexes are long lived (29). However, when the same
cells are analyzed by confocal laserscanning microscopy a
rapid segregation of the PE- and the FITC signals can be
observed. Thus, already after 15 min of incubation at 37 C
a substantial portion of the PE signal accumulates in intra-
cellular compartment which has recently been shown to
represent early endosomes (29). In contrast, the FITC sig-
nal remains on the cell surface. Identical data were obtained
with nontransfected Jurkat T cells (not shown). Collec-
tively, these data corroborate previous data showing that
TCR/CD3 complexes are rapidly internalized and sub-
jected to the recycling pathway without being degraded
(29–31). The difference between the rather moderate re-
duction of TCR expression after BFA treatment shown in
Fig. 4 A versus the apparently rapid and strong intracellular
accumulation of CD3  shown in Fig. 4 B could indicate
that binding of the PE-labeled mAb to CD3  accelerates
spontaneous endocytosis of the TCR.
However, when the same experiment was applied to
Jurkat T cells overexpressing TRIM, we observed that the
PE-labeled CD3  molecules were internalized at a much
slower rate than in the vector-transfected cells. Indeed,
confocal laserscanning microscopy revealed that in cells
overexpressing TRIM, a fraction of the PE-labeled CD3 
molecules were still present on the cell surface and colocal-
ized with the TCR- /  heterodimers even after 90 min of
incubation at 37 C (Fig. 4, C and D). Further analysis of
the transfectants using TRIM mAb revealed that only in
cells overexpressing TRIM was internalization of the PE-
labeled CD3  molecules abolished (Fig. 4 D). From these
data, we conclude that overexpression of TRIM primarily
upregulates TCR expression on the cell surface by inhibit-
ing its spontaneous internalization.
TRIM Preferentially Associates with the TCR-  Chain.
We next wished to determine how TRIM interacts with
the TCR/CD3/  complex. To assess this question, we ana-
lyzed TRIM and CD3  immunoprecipitates prepared from
digitonin lysates of Jurkat T cells for the relative amounts of
CD3  and TCR- , respectively, by Western blotting. Fig.
5 A depicts that identical amounts of CD3  and TCR-  are
detectable in CD3  immunoprecipitates. In contrast, under
the same experimental conditions,  10 times more   than
CD3  coprecipitate with TRIM (as judged from densito-
metric analysis of the shown blot). Similar results as shown
here for Jurkat T cells are obtained when the immunopre-
cipitates are prepared from resting peripheral blood T cells
(not shown). This suggests that TRIM interacts with the
TCR preferentially via the TCR-  chain.
To further corroborate this hypothesis, we also analyzed
CD3  or anti-FLAG immunoprecipitates prepared from
vector- or F-TRIM–transfected Jurkat T cells by Western
blotting for coprecipitation of the individual components
of the CD3 complex and the   chains. Fig. 5 B demon-
strates that, even after overexpression, large amounts of en-
dogenous   coprecipitate with TRIM, whereas only low
amounts of CD3  are detectable in the TRIM immuno-
precipitates. Interestingly, the TRIM-associated fraction of
CD3  exclusively consisted of CD3 /  heterodimers. Al-
though the CD3  Ab that was used in these experiments
had a somewhat weaker reactivity compared with the
CD3  Ab, we did not observe coprecipitation of CD3 
with TRIM in several experiments and even after pro-
longed overexposure of the autoradiograph. Thus, also
when overexpressed in Jurkat T cells, TRIM preferentially
interacts with the TCR-  chain and to a much lesser extent
with the CD3 /  heterodimer.
We next determined whether TRIM associates with  
also in the absence of other TCR components. Fig. 5, C
and D, demonstrate that when coexpressed in COS7 cells,
TRIM and   coprecipitate with each other and colocalize
in the transfectants. This suggests that TRIM and   can in-
teract with each other in the absence of other components
of the TCR. Importantly, the right panel of Fig 5 C also
demonstrates that TRIM does not need additional compo-
nents of the TCR (including  ) to be expressed on the cell
surface. This was confirmed using a series of well-charac-
terized Jurkat mutant clones, each of which lack one com-
ponent of the TCR/CD3 complex and thus does not ex-
press TCR complexes on the cell surface (Fig. 5 E). In all
three Jurkat mutants tested, TRIM showed the same sub-
cellular localization as in wild-type Jurkat T cells, namely a
preferential localization at the plasma membrane and an in-
tracellular compartment.
The Molecular Basis for the Association between TRIM and  .
To determine the region(s) of TRIM that is/are required
for its association with   and for upregulation of TCR ex-
pression on the cell surface, we overexpressed chimeric
FLAG-tagged TRIM molecules (in which individual parts
of TRIM were replaced by the corresponding regions of
LAT; Fig. 6 A) in Jurkat cells and assessed the expression
levels of the TCR on the cell surface (Fig. 6 C) and the as-
sociation between TRIM and endogenous   by anti-FLAG
Western blot analysis of   immunoprecipitates (Fig. 6 D).
These experiments revealed that, as already shown above,
F-TRIM strongly associates with   and facilitates upregula-
tion of TCR expression. Importantly, almost identical re-
sults are obtained when a TRIM mutant, in which the
three cytoplasmic tyrosine residues representing the major
sites of phosphorylation are mutated to phenylalanine (F-
15.5; Fig. 6, A–C), is overexpressed in Jurkat T cells. This
indicates that all three tyrosine residues of TRIM are dis-
pensable for the association between TRIM and   and also
for TRIM-mediated upregulation of TCR expression.
However, despite comparable levels of expression (not
shown), none of the TRIM/LAT chimeras investigated is
capable of mediating upregulation of TCR expression in a
similar fashion as wild-type TRIM or the F-15.5 mutant. In
fact, when only a single domain of TRIM is replaced by the
corresponding portion of LAT (LTT-, TLT-, and TTL chi-
meras), the ability of TRIM to upregulate TCR expression
and to associate with   is already largely impaired. Of the
three chimeras tested, the TTL chimera even downregulates
TCR expression to some extent (Fig. 6 C), although the co-1276 Regulation of TCR Expression by TRIM
Figure 4. Inhibition of spontane-
ous TCR internalization by TRIM.
(A) Vector transfectants or TRIM
transfectants were treated for 90 min
with BFA at 37 C. Subsequently,
the expression of the TCR- / 
heterodimer was determined by in-
direct immunofluorescence. ctrl.,
control. (B and C) Vector transfec-
tants or TRIM transfectants were
externally labeled on ice with PE-
labeled CD3  mAb UCHT-1. After
washing the temperature was shifted
to 37 C for the indicated periods of
time. After incubation at 37 C, the
temperature was again lowered to
4 C and cells were externally labeled
with the anti-TCR mAb C305
(IgM) followed by FITC-labeled
goat anti–mouse IgM serum. Cells
were then analyzed by flow cytome-
try (B) or by confocal laserscanning
analysis (C). sTCR, surface TCR.
(D) TCR internalization is only
downregulated in Jurkat T cells
overexpressing TRIM. Jurkat T cells
transfected with a plasmid encoding
TRIM were labeled on ice with
UCHT1-PE as described above. Af-
ter washing, cells were either incu-
bated on ice (left) or incubated for
15 min at 37 C (right). Cells were
then permeabilized and stained with
biotinylated TRIM-4 mAb followed
by detection using streptavidin Cy2.1277 Kirchgessner et al.
Figure 4. (continued).
Figure 5. TRIM preferentially associates with the TCR-  chain. (A) 3   107 Jurkat T cells were lysed in digitonin-containing buffer and subjected to
TRIM or CD3  (OKT-3) immunoprecipitation. Two different monoclonal TRIM Abs (TRIM-4 and TRIM-7) were used for immunoprecipitation.
Precipitates were analyzed by sequential anti-CD3  (a polyclonal rabbit antiserum), anti-  (hamster mAb H146), and anti-TRIM (a polyclonal rabbit an-
tiserum) Western blotting. (B) Jurkat cells were transiently transfected with empty vector or with a cDNA construct encoding FLAG-tagged wild-type
TRIM. 40 h after transfection, cells were lysed in digitonin-containing buffer and subjected to anti-CD3  or anti-FLAG immunoprecipitation followed
by sequential anti-CD3 , anti-CD3 , anti-CD3 , or TCR-  (hamster mAb H146) Western blotting. (C) COS cells were transiently transfected with a
cDNA coding for human TCR-  together with a construct encoding FLAG-tagged wild-type TRIM (F-TRIM). After 40 h of incubation, double im-
munofluorescence was applied on the transfected cells using anti-  (mAb 6B10.2, green fluorescence, Cy2) and anti-TRIM (the affinity-purified poly-
clonal antiserum, red fluorescence, Texas red) Abs. (D) A portion of the transfectants was lysed in digitonin-containing buffer and subjected to   immu-
noprecipitation (using mAb 6B10.2) followed by anti-TRIM immunoblotting (using the polyclonal antiserum). (E) Wild-type (WT) Jurkat T cells, as
well as the Jurkat variants 18B3 (lacking expression of TCR- ), JBN (lacking expression of TCR- ), and JGN (lacking expression of CD3 ) were as-
sessed for the subcellular localization of TRIM (using mAb TRIM-4) by confocal laserscan microscopy.1278 Regulation of TCR Expression by TRIM
Figure 6. The molecular basis for association between
TRIM and TCR- . (A) Scheme depicting the various TRIM/
LAT chimeras that were analyzed in this figure. The chimeras
are composed of parts TRIM (labeled with T) or LAT (labeled
with L). The three-letter code stands for the extracellular (EC),
transmembrane (TM), and intracellular (IC) domains, respec-
tively. (B) Jurkat T cells were transfected with cDNAs encod-
ing F-TRIM or the F.15.5 mutant in which the potential ty-
rosine based signaling motifs (Y63GNL, Y79EQM, and Y110ASL)
were mutated to phenylalanine (F). 40 h after transfection, the
cells were briefly treated with pervanadate (2 ). Then, anti-
FLAG immunoprecipitates were prepared which were first ana-
lyzed by anti-PTYR immunoblotting. Blots were then stripped
and reprobed with anti-FLAG Ab. Note that mutation of the
three tyrosines slightly alters the molecular weight of the F-15.5
mutant. (C) cDNA constructs encoding the various TRIM/
LAT chimeras shown in A were transfected into Jurkat T cells
by electroporation. 40 h later, the expression of CD3  on the
cell surface was determined by flow cytometry. (D) In parallel,
cells were lysed in digitonin-containing buffer, and subjected to
  (mAb 6B10.2) immunoprecipitation and nonreducing SDS-
PAGE followed by anti-FLAG immunoblotting. Note that the
differences in molecular weight of the TRIM/LAT chimeras
results from the different length of the TRIM and LAT extra-
cellular and cytoplasmic domains, respectively. (E) Subcellular
localization of   and TRIM/  colocalization in Jurkat T cells
transfected with cDNA encoding F-TRIM or the F-TTL chi-
mera. Note that the TTL chimera is not properly transported to
the cell membrane but colocalizes with   inside the cell.1279 Kirchgessner et al.
precipitation experiments indicate that this chimera weakly
interacts with   (Fig. 6 D). Analysis of the subcellular local-
ization of the TTL chimera revealed that it cannot be prop-
erly transported to the plasma membrane and is to a large
extent retained in the cytoplasm (Fig. 6 E). Apparently, its
weak association with   is sufficient to prevent some   chains
to be transported to the plasma membrane, thus resulting in
downregulation of TCR expression. It is also interesting to
note that in several experiments we observed that the LTT
chimera associates with   as a dimeric molecule (Fig. 6 D),
although this chimera does not possess the cysteine residue
(C7) that normally confers TRIM dimerization (thus, LTT
would be expected to run only as a monomeric molecule of
 30 kD even under nonreducing conditions). For reasons
that will be discussed below, we think that the   association
of the LTT chimera as a dimer is due to a particular property
of the TRIM transmembrane domain.
The interaction with   is completely lost when TRIM
chimeras are expressed in which two domains of TRIM are
replaced by LAT (LTL- and LLT chimeras). Consequently,
these chimeras do not influence the expression levels of the
TCR on the cell surface at all. Similarly, the transmem-
brane adaptor proteins SIT and LAT do not associate with
  and thus do not alter TCR expression.
Interestingly, we found that a TRIM mutant in which
the transmembrane domain of TRIM was deleted (F-
 TM) completely fails to associate with   and to alter TCR
expression (Fig. 6, C and D). This finding somehow con-
tradicted the results that were obtained with the TLT-, the
LTT-, and the TTL chimeras, namely that the presence of
two domains of TRIM allows a weak interaction with  .
However, confocal laserscanning analysis revealed that the
 TM mutant diffusely localizes within the cell, including
the nuclear compartment (data not shown). This particular
subcellular localization might explain its inability to associ-
ate with  . Nevertheless, from the data shown in Fig. 6 we
draw the following conclusions: first, upregulation of TCR
expression is a particular property of TRIM and cannot be
mediated by other transmembrane adaptor proteins such as
SIT or LAT. Second, in order to associate with   and to fa-
cilitate TCR expression on the cell surface, all three do-
mains of TRIM are required.
TCR Expression in Jurkat Cells Stably Overexpressing
TRIM. The experiments described above were per-
formed using transiently transfected Jurkat T cells. To ex-
clude the possibility that upregulation of TCR expression
after overexpression of F-TRIM could only be observed in
transiently transfected Jurkat T cells, we established a series
of transfectants stably overexpressing F-TRIM. Fig. 7 A
demonstrates that a representative Jurkat clone overexpress-
ing F-TRIM also expresses higher amounts of TCR and
CD3  on the cell surface than a vector transfectant. Confo-
cal laser scan analysis further revealed that also in this cell
line the majority of endogenous   is localized at the plasma
membrane (Fig. 7 B). Identical results were obtained for six
additional clones of each group. On average, TRIM trans-
fectants expressed 1.6 times more TCRs on the cell surface
compared with the vector transfectants (Fig. 7 C). How-
ever, it is important to note that after prolonged periods of
cell culture, the transfectants downregulated TCR expres-
sion to a certain extent. The molecular basis of this coun-
terregulation is not known at present.
Enhanced TCR-mediated Ca2  Flux in Jurkat T Cells Stably
Expressing F-TRIM. Next, it was important to determine
whether overexpression of TRIM and the resulting upreg-
ulation of TCR expression would alter the signaling capac-
ity of the TCR. To assess this, we compared TCR-medi-
ated Ca2  fluxes in Jurkat clones stably overexpressing
F-TRIM with those obtained after TCR triggering of vec-
tor transfectants. Fig. 7 D indicates that TCR triggering of
the stably transfected clones resulted in an approximately
twofold higher level of Ca2  compared with the vector
transfectants. However, the amplification of TCR-medi-
ated Ca2  fluxes mediated by overexpression of TRIM was
not influenced by Tyr to Phe substitutions, as almost iden-
tical Ca2  responses were observed in the F-TRIM trans-
fected cells compared with cells overexpressing the F-15.5
mutant. These data also suggest that the capacity of TRIM
to enhance TCR-mediated signal transduction does not
depend on the expression of the tyrosine-based signaling
motifs in its cytoplasmic domain.
Discussion
In this report we provide further evidence that the re-
cently cloned transmembrane adaptor protein TRIM repre-
sents a novel integral component of the TCR/CD3/  com-
plex (19). Thus, besides coprecipitating with the TCR, our
results indicate that TRIM but not other signaling mole-
cules such as LPAP and SKAP-HOM specifically cocaps
with the TCR (Fig. 1). Biochemical analysis of TRIM im-
munoprecipitates prepared from Jurkat T cells further indi-
cated that the major component of the TCR complex that
is present in TRIM immunoprecipitates is the TCR-  chain
(Fig. 5 A). From these data, as well as from the observation
that the preferential association between TRIM and   was
also observed after transient overexpression of TRIM (Fig.
5 B), we conclude that in mature T cells, TRIM preferen-
tially interacts with the TCR via TCR- . The association
between TRIM and   is most likely direct and does not de-
pend on the expression of other components of the CD3
complex, as it also occurs in COS cells (Figs. 5, C and D).
However, we certainly cannot exclude the possibility that
COS cells express an unknown molecule that facilitates the
association between TRIM and  . In addition, it is un-
known at present whether TRIM associates with the  
chain already in the cytosol or only after the complete
TCR/CD3/  complex has reached the cell surface. Clearly,
additional studies are required to elucidate this question.
However, confocal laserscanning analysis of COS7 overex-
pressing TRIM or of Jurkat variants lacking cell surface ex-
pression of the TCR (Fig. 5, C and E) clearly indicated that
TRIM does not need additional components of the TCR/
CD3/  complex to be transported to the cell surface.
The most striking finding of our work is that transient
and stable overexpression of TRIM in Jurkat T cells in-1280 Regulation of TCR Expression by TRIM
duces an approximately twofold higher expression of the
TCR/CD3 complex compared with wild-type Jurkat T
cells (Figs. 2, 6, and 7) and that these cells responded to-
wards TCR triggering with elevated levels of Ca2  mobili-
zation. Comparative confocal laser scanning analysis of
wild-type Jurkat T cells and TRIM transfectants indicated
an altered subcellular localization of the TCR-  chain in
Jurkat cells overexpressing TRIM (Fig. 3, B and C, and
Fig. 7 D). Thus, in accordance with a recent publication
(16), we observed that in wild-type Jurkat T cells, only half
of endogenous   localizes at the plasma membrane, whereas
the other half is retained in cytoplasm. In marked contrast,
upon overexpression of TRIM, the majority of endoge-
nous   localizes at the plasma membrane (Fig. 3, B and C).
Upregulation of TCR expression by TRIM and enhanced
presence of   at the plasma membrane requires a physical
association between TRIM and  . This conclusion is
drawn from experiments which demonstrated that overex-
pression of TRIM chimeras that do not associate with   are
also unable to alter TCR expression (Fig. 6). Surprisingly,
we observed that the association between TRIM and   ap-
parently involves all three domains of TRIM. Thus, re-
placement of any portion of TRIM by the corresponding
part of the transmembrane adaptor protein LAT produced
a TRIM chimera, which had largely lost its ability to asso-
ciate with   (and to upregulate TCR expression).
With regard to the extracellular and the transmembrane
domains of TRIM, this finding is not surprising. Bolliger et
al. have recently identified a dimerization motif (Fig. 8)
within the transmembrane domain of  , which has first
been described in glycophorin A, a cell surface receptor ex-
pressed on erythrocytes (32). This dimerization motif al-
lows formation of SDS-stable protein dimers in the absence
of disulfide bonds linking the two polypeptide chains. The
Figure 7. Characterization of Jurkat clones stably overexpressing TRIM. (A) and (B) CD3  and TCR- /  expression (A) and subcellular localization
of   (B) in a representative stably transfected Jurkat T clone (pos.; clone 2D1) compared with a transfectant not expressing TRIM (neg.; clone 2C3). (C)
Mean channels of CD3  expression in six vector transfectants and in six TRIM transfectants as determined by flow cytometry. (D) Enhanced TCR-
mediated Ca2  flux in Jurkat T cells stably expressing F-TRIM and the F-15.5 mutant.1281 Kirchgessner et al.
integrity of the dimerization motif in the transmembrane
domain of   (the amino acid sequence is: GLxxxxGVxxT)
seems to be necessary to facilitate reexpression of the
TCR/CD3 complex in a  -deficient T cell hybridoma
(32). Importantly, a similar dimerization motif as in   is
also present in the transmembrane domain of TRIM
(GLxxxxGLxxV). The assumption that this dimerization
motif might be of functional relevance is supported by our
repeated observation that treatment of TRIM with reduc-
ing agents alone (e.g., 2-ME) is not sufficient to generate its
monomeric form even in SDS-containing buffers (unpub-
lished data). Moreover, a chimeric TRIM molecule in
which the extracellular domain of TRIM (which normally
carries the cysteine residue (C7) that mediates TRIM
dimerization via the S-S bridge) was replaced by the corre-
sponding part of the transmembrane adaptor protein LAT
still can associate with   as an SDS-stable dimer (Fig. 6 D).
These data could indicate that TRIM can only associate
with   as a dimeric molecule, and that TRIM dimerization
is mediated in two different ways, namely (a) the dimeriza-
tion motif within the transmembrane domain and (b) the
extracellular domain of TRIM including C7. With regard
to the latter point, it is important to note that preliminary
data obtained in our laboratory indicate that mutation of C7
generates a monomeric TRIM molecule, which is no
longer able to associate with   and consequently does not
alter the expression level of the TCR. Moreover, it is im-
portant to note that recent data also suggest that the expres-
sion and function of the TCR is not only dependent on the
integrity of the transmembrane domain of   but also on its
extracellular domain (33, 34). Whether or not the associa-
tion between TRIM and   contributes to this finding is un-
clear at present but represents an intriguing possibility.
In contrast to a requirement of both the extracellular and
transmembrane domains of TRIM to allow a stable interac-
tion between TRIM and  , we were surprised to observe
that this interaction apparently also involves the cytoplas-
mic domain of TRIM (Fig. 6, C and D). However, a com-
parison of the mouse and human TRIM amino acid
sequences indicates that the extracellular domain, the
transmembrane domain, and the first 11 cytoplasmic amino
acids directly downstream of the transmembrane domain
are highly conserved between the two species. In marked
contrast, the remaining parts of TRIM show a much lesser
conservation (95 vs. 62%, respectively; Fig. 8). This could
indicate that the membrane proximal cytoplasmic part of
TRIM is also involved in its association with  . However,
our attempts to clarify this question directly were so far un-
successful because truncated TRIM molecules in which the
majority of the cytoplasmic domain was deleted could not
be expressed stably in Jurkat T cells.
Analysis of the fate of externally labeled TCR compo-
nents by confocal laserscanning analysis revealed that TRIM
upregulates TCR expression on the cell surface by inhibit-
ing spontaneous TCR internalization (Fig. 4). The precise
mechanism underlying this phenomenon is not yet clear.
However, it has been proposed that spontaneous internal-
ization of the TCR/CD3/  complex in nonactivated T
cells is mainly regulated by a motif within the cytoplasmic
domain of CD3  that becomes phosphorylated by protein
kinase C (30, 31, 35). Moreover, it has been reported that
CD16/CD3  chimeras capable of associating with TCR- 
can be stably expressed on the cell surface and have a low
rate of spontaneous internalization whereas CD4/CD3 
chimeras, which cannot interact with   are rapidly internal-
ized resulting in low levels of expression on the cell surface
(36). These findings collectively indicate that, via its associ-
ation with the TCR, the   chain is capable of influencing
the function of the internalization motif within CD3  and
that   is involved in regulating cycling of the TCR.
Therefore, one possibility to explain upregulation of
TCR expression after overexpression of TRIM would be
that TRIM inhibits TCR internalization by enhancing the
amounts of plasma membrane–associated  , which then al-
ters the function of the CD3  internalization motif.
Whether this is due to masking the phosphorylation site
within the motif, to displacement of the serine kinase
phosphorylating CD3 , or to recruitment of a serine phos-
phatase that dephosphorylates the motif, requires further
analysis. However, our data suggest that, by altering the
expression levels of TRIM, T cells could regulate the lev-
els of cell surface–expressed TCR molecules and, via this
mechanism, T cell responsiveness towards externally ap-
plied stimuli.
Previously we have reported that after phosphorylation
by src kinases, TRIM recruits the regulatory p85 subunit of
PI3 kinase via a phosphorylated YxxM motif (19). In addi-
tion, most recent experiments performed in our laboratory
revealed that, in addition to PI3 kinase, tyrosine-phos-
phorylated TRIM associates with at least two unknown
polypeptides of 43 and 50 kD (unpublished data). It is
tempting to speculate that the complex between TRIM,
PI3 kinase, and the two unknown polypeptides serves a
Figure 8. (A) Comparison between human and mouse TRIM indica-
ting a strong conservation of the extracellular domain, the transmembrane
region, and the first 10 cytoplasmic amino acids (boxed). (B) Similarity
between the putative dimerization motifs in the transmembrane domains
of  , and TRIM. The transmembrane domains are indicated by solid
lines, and the putative dimerization motif by a dotted box. The Gen-
Bank/EMBL/DDBJ accession no. for mouse TRIM is AJ29769.1282 Regulation of TCR Expression by TRIM
signaling function during T cell activation. However, so far
we have not been able to dissect which signaling pathway is
initiated/altered by TRIM. Thus, the data shown in this
report demonstrated that a TRIM mutant in which all ty-
rosine residues are mutated to phenylalanine (F-15.5) has
exactly the same properties as wild-type TRIM (at least
with regard to regulation of TCR expression [Fig. 6], inhi-
bition of spontaneous TCR internalization [not shown],
and TCR-mediated induction of Ca2  fluxes [Fig. 7]).
Moreover, analysis of Jurkat T cells that stably overexpress
the F-15.5 mutant revealed that these cells are indistin-
guishable from Jurkat T cells overexpressing wild-type
TRIM. This applies, for example, for TCR-mediated in-
duction of mRNA expression coding for several cytokines
or upregulation of CD69 expression after TCR triggering.
Thus, additional studies are required to elucidate the signal-
ing function of the cytoplasmic domain of TRIM.
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